Bouchard opened a discussion on sequencing therapies in MM, noting that CAR T-cell therapy and bispecific antibodies each ...

Long-term remission in multiple myeloma—a blood cancer once considered incurable—is finally becoming a reality. A single ...

A dexamethasone-sparing regimen involving lenalidomide (Revlimid) and the anti-CD38 drug daratumumab (Darzalex) was safe and ...

Scientists discovered that inhibiting the enzyme STK17B forces multiple myeloma cells into iron-driven death and makes ...

As many as one third of newly diagnosed multiple myeloma (MM) cases are classified as high risk, with widely varying rates of ...

Cevostamab showed a 93% MRD-negative complete response rate at 1 year post CAR T-cell therapy in heavily pretreated multiple ...

Iberdomide combined with standard therapies showed a statistically significant improvement in minimal residual disease (MRD) ...

Intensive cytotoxic bridging therapy is linked to delayed recovery after CAR T-cell therapy for multiple myeloma.

At a live event in White Plains, New York, Adriana Rossi, MD, assistant professor of medicine and director of CAR T and the Stem Cell Transplant Clinical Service at the Center of Excellence for ...

While it’s not as well-known as, say, leukemia or melanoma, multiple myeloma is the second most common blood cancer in adults, according to the Cancer Research Institute. “Multiple myeloma is a cancer ...

Although multiple myeloma is often considered incurable, the development of highly effective new therapies is creating a real possibility of a cure for some patients. Current 4-drug upfront regimens, ...

Researchers at Duke University have shown that blocking an enzyme involved in iron regulation not only kills multiple myeloma cancer cells, but also increases the effectiveness of current therapies ...